US FDA approves new therapy for myelodysplastic syndromes a rare form of blood cancers, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

The US FDA granted the approval of Tibsovo to Servier Pharmaceuticals LLC and RealTime IDH1 Assay to Abbott Laboratories. MDS are a rare form of blood cancers that can occur when the mutations in the bone marrow progenitor cells (cells that form blood) lead to insufficient numbers of healthy blood cells., The US FDA granted the approval of Tibsovo to Servier Pharmaceuticals LLC and RealTime IDH1 Assay to Abbott Laboratories. MDS are a rare form of blood cancers that can occur when the mutations in the bone marrow progenitor cells (cells that form blood) lead to insufficient numbers of healthy blood cells., , Read More

Leave a Reply

Your email address will not be published. Required fields are marked *